Lesli A Kiedrowski
Overview
Explore the profile of Lesli A Kiedrowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1083
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grivas P, Kiedrowski L, Sonpavde G, Gupta S, Thomas R, Gourdin T, et al.
Bladder Cancer
. 2024 Jul;
7(2):143-148.
PMID: 38994535
Detecting genomic alterations (GAs) in advanced urothelial carcinoma (aUC) can expand treatment options by identifying candidates for targeted therapies. Erdafitinib is FDA-approved for patients with platinum-refractory aUC with activating mutation...
2.
Nakazawa M, Harada G, Ghanem P, Bubie A, Kiedrowski L, Murray J, et al.
Cancer Res Commun
. 2024 Feb;
4(3):786-795.
PMID: 38407352
Significance: In a large-scale, contemporary cohort of patients with advanced ALK-positive NSCLC, we evaluated molecular characteristics and their impact on acquired resistance mutations and clinical outcomes. Our findings that certain...
3.
Dagogo-Jack I, Kiedrowski L, Lennerz J
Lung Cancer
. 2023 Oct;
186:107383.
PMID: 37813016
Objectives: MET amplification is a common mechanism of resistance to second- and third-generation anaplastic lymphoma kinase (ALK) inhibitors. In case series of MET-amplified ALK-rearranged (ALK + ) lung cancer, durability...
4.
Kasi P, Bucheit L, Liao J, Starr J, Barata P, Klempner S, et al.
JCO Precis Oncol
. 2023 Sep;
7:e2300118.
PMID: 37769226
Purpose: Immune checkpoint inhibitors are approved for advanced solid tumors with microsatellite instability-high (MSI-H). Although several technologies can assess MSI-H status, detection and outcomes with circulating tumor DNA (ctDNA)-detected MSI-H...
5.
Dagogo-Jack I, Kiedrowski L, Heist R, Lin J, Meador C, Krueger E, et al.
JTO Clin Res Rep
. 2023 Aug;
4(8):100534.
PMID: 37533439
Introduction: amplification is a potentially actionable resistance mechanism in -rearranged (ALK+) lung cancer. Studies describing treatment outcomes of this molecular subgroup are lacking. Methods: We assembled a cohort of patients...
6.
Brown T, Yablonovitch A, Till J, Yen J, Kiedrowski L, Hood R, et al.
Clin Cancer Res
. 2023 Jul;
29(24):5207-5216.
PMID: 37486343
Purpose: PARP inhibitors (PARPi) provide an effective maintenance option for patients with BRCA- or PALB2-mutated pancreatic cancer. However, mechanisms of PARPi resistance and optimal post-PARPi therapeutic strategies are poorly characterized....
7.
Swami U, Zimmerman R, Nussenzveig R, Hernandez E, Jo Y, Sayegh N, et al.
Front Oncol
. 2022 Oct;
12:966534.
PMID: 36185208
-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to -mutated prostate cancer. The reason for this differential response is not...
8.
Ezeife D, Spackman E, Juergens R, Laskin J, Agulnik J, Hao D, et al.
Ther Adv Med Oncol
. 2022 Aug;
14:17588359221112696.
PMID: 35923926
Background: Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor circulating tumor DNA beyond tissue testing (TT) alone in advanced non-small cell lung cancer (NSCLC) patients. We...
9.
Shiba-Ishii A, Johnson T, Dagogo-Jack I, Mino-Kenudson M, Johnson T, Wei P, et al.
Nat Cancer
. 2022 Jun;
3(6):710-722.
PMID: 35726063
Lorlatinib is currently the most advanced, potent and selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor for the treatment of ALK-positive non-small cell lung cancer in the clinic; however, diverse...
10.
Yeung V, Kim C, Kiedrowski L, Liu S, Reuss J
Transl Lung Cancer Res
. 2022 Mar;
11(1):111-116.
PMID: 35242632
Molecular characterization of non-small cell lung cancer (NSCLC) has led to marked improvements in the treatment of patients with advanced disease who harbor driver mutations, including those with alterations in...